Interventional News’ top 10 most popular stories of May 2022

8879

TOP 10

May’s top 10 stories on Interventional News include a report of long-term data on the safety of femoropopliteal endovascular treatment with paclitaxel-coated devices, FDA clearance of a new fibred detachable coil, and coverage of two developments in the use of robotics for performing interventions with increased accuracy.

 

1) Magneto Thrombectomy Solutions announces successful first-in-human results for treatment of pulmonary embolism

Magneto Thrombectomy Solutions (Magneto), a medical devices company developing thrombectomy solutions for the treatment of ischaemic stroke and pulmonary embolism, presented successful first-in-human (FIH) results showing safety and feasibility of the eTrieve system, a catheter based on electric fields for removing blood clots, in patients with acute pulmonary embolism (PE).

 

2) RANZCR releases statement on iodinated contrast media shortage

The Royal Australian and New Zealand College of Radiologists (RANZCR) has issued a statement addressing the Australian and global shortage of iodinated contrast media.

 

3) New long-term data of paclitaxel devices continue to show no increased mortality compared to non-drug coated devices

New long-term data from the SAFE-PAD (Safety assessment of femoropopliteal endovascular treatment with paclitaxel-coated devices) study were presented as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions (19–22 May, Atlanta, USA).

 

4) Shockwave IVL maintains superiority to angioplasty in calcified peripheral disease at two years

Shockwave Medical announced that long-term data from the Disrupt PAD III trial found that superior vessel preparation with intravascular lithotripsy (IVL) led to excellent long-term outcomes out to two years with preservation of future treatment options compared to percutaneous transluminal angioplasty (PTA) in the treatment of calcified peripheral arterial disease (PAD).

 

5) Micromate now available to use with CT guidance thanks to planning and navigation station

The new addition to Micromate makes it possible for physicians to rely on pre- and intraoperative scans to plan the intervention, the company behind the robot Interventional Systems, announced in a press release. These planning capabilities can then be leveraged to navigate and guide instruments to the trajectory automatically with submillimetre accuracy.

 

6) Interventional Systems announces strategic collaboration agreement with the Johns Hopkins University’s Whiting School of Engineering

Interventional Systems recently announced a new collaboration with Johns Hopkins University (Baltimore, USA) in a company press release. The research team at Johns Hopkins, led by Axel Krieger and Lidia Al-Zogbi, will not only investigate ways to improve the Micromate system but leverage the platform nature of the robot and identify new anatomical locations or applications, whose accuracy or safety issues could be addressed by using a robot.

 

7) Boston Scientific Receives FDA Clearance for the EMBOLD Fibered Detachable Coil

Boston Scientific has received US Food and Drug Administration (FDA) 510(k) clearance for the EMBOLD Fibered Detachable Coil, which is indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature. The first procedure using the device was performed recently at the University of Alabama (Birmingham, USA).

 

8) CLS Americas debuts fusion-guided TRANBERG focal laser ablation system at AUA 2022

CLS Americas announced it will debut its office-based, magnetic resonance (MR)/ultrasound (US) fusion-guided, TRANBERG Thermal Therapy System for high-precision focal laser ablation of soft tissue, such as prostate cancer tumours, at the American Urological Association (AUA) 2022 Conference (May 13–16, New Orleans, USA).

 

9) CATHI joins with VSS to launch world’s first online training programme for endovascular simulation  

Germany-based endovascular simulator supplier CATHI has joined forces with UK-based Vascular Simulation Solutions (VSS) to offer the world’s first online training masterclass using endovascular simulation coupled to a structured curriculum, the company said in a press release.

 

10) First patient enrolled in PERIO-02 trial of SD-101 delivery via pressure-enabled drug delivery for hepatocellular carcinoma or intrahepatic cholangiocarcinoma

TriSalus Life Sciences announced the enrolment of the first patient in its Pressure-Enabled Regional Immuno-Oncology (PERIO-02) clinical study in a press release.


LEAVE A REPLY

Please enter your comment!
Please enter your name here